My WebLink
|
Help
|
About
|
Sign Out
Home
Browse
Search
Fully executed contract
>
Meetings
>
2026
>
06. June
>
2026-06-02 10:00 AM - Commissioners' Agenda
>
Fully executed contract
Metadata
Thumbnails
Annotations
Entry Properties
Last modified
6/11/2026 10:39:56 AM
Creation date
6/11/2026 10:39:48 AM
Metadata
Fields
Template:
Meeting
Date
6/2/2026
Meeting title
Commissioners' Agenda
Location
Commissioners' Auditorium
Address
205 West 5th Room 109 - Ellensburg
Meeting type
Regular
Meeting document type
Fully Executed Version
Supplemental fields
Item
Request to Approve Amendment No. 5 to Contract K5885 with Washington State Health are Authority, for the Medication for Opioid Use Disorder (MOUD) and Medications for Alcohol Use Disorder (MAUD) in the Jail
Order
6
Placement
Consent Agenda
Row ID
144971
Type
Agreement
There are no annotations on this page.
Document management portal powered by Laserfiche WebLink 9 © 1998-2015
Laserfiche.
All rights reserved.
/
13
PDF
Print
Pages to print
Enter page numbers and/or page ranges separated by commas. For example, 1,3,5-12.
After downloading, print the document using a PDF reader (e.g. Adobe Reader).
View images
View plain text
. Docusign Envelope lD: 700826AD-3CE3-815C-8194-013EF364M04 <br />ATTACHMENT 1.A <br />EXAMPLE - MOUD & MAUD in Jails Program Monthly Progress Report <br />NOTE: Example below provided for reference only , the HCA Contract Manager will provide the fillable form for <br />Contractor use prior to the July 1 ,2026, implementation date. <br />1. INTAKE <br />n Screen all newly admitted individuals for risk of acute opioids hol upon intake <br />n MOUD3' MAUD4 and other medications which sup , such as <br />alpha-2 ad renergic agon ists (e.9., lofexidine),gesics, and fluid and <br />electrolyte replacement (e.9., Gatorade@) must o charge to the individual. <br />! Offer initiation of MOUD treatment to in lly dependent on opioids, may have <br />withdrawal symptoms,or have disclosed recent withdrawal. Facilities shall not <br />require tapering from the illicit opioid un <br />! Offer treatment for withdrawal with entering the facility who are <br />physically dependent on alcohol, if clinica <br />n Continue MOUD and MAUD for taking these medications upon entering the <br />facility. Continue the individual at the same dose unless ordered otherwise by <br />the prescriber based on clinical n lowing exceptions is applicable <br />a lnjectable long-acting naltrexone to an equivalent oral dose untiljust prior to <br />release at which ti ble form restarted <br />lnjectable long-acti converted to an equivalent oral dose until just prior to <br />release at which time all be restarted <br />a Oral rne may rted to any of the three formulations available: film, tablet with <br />naloxone,without <br />adone may be transitioned to buprenorphine if one of the <br />Contractor licensed Opioid Treatment Program (OTP) an d the nearest OTP willing to <br />a <br />a lf the <br />foll <br />o <br />laborate jailto provide methadone is not within reasonable driving distance from the <br />n d the ja not have nursing staff on site seven (7) days a week. The individual mustil, <br />be <br />3 Methadone, buprenorphi naltrexone <br />a Naltrexone, acamprosate <br />hadone prior to release if they plan to resume methadone in the <br />rs P within reasonable distance of the individual's release residence <br />TCONTRACTOR NAME: <br />CONTRACT FUNDING END:CONTRACT FUNDING START:MONTH REPORTING ON:.rrr-ffi#ffiJuly 1 ,2026 <br />HCA Contract No. K5885-05 Page 10 of l3
The URL can be used to link to this page
Your browser does not support the video tag.